Hyderabad: Bharat Biotech International Ltd has launched REGEN-D, a recombinant epidermal growth factor (rhEGF). The product is used in diabetic foot care, burn injuries and skin grafts.

REGEN-D is being offered in two strengths – REGEN-D 150 for diabetic foot ulcers and REGEN-D 60 for burns and skin grafts.

"According to the estimates of World Health Organisation (WHO), diabetes will become one of the world’s main disablers and killers within the next 25 years. The WHO’s latest estimate for diabetic patients worldwide, in 2000 is 177 million. In India, alone, patients undergo 40,000 amputations every year due to diabetic foot ulcers. In this context REGEN-D 150 manufactured indigenously will tremendously impact the lives of a vast patient population in affected with the Ulcers." Bharat’s CMD Dr Krishna M Ella said.